DISCOUNT OPTIONSSCHEIN - FRESENIUS Stock

Certificat

DE000VM3AUL7

Delayed Deutsche Boerse AG 04:34:12 2024-05-29 EDT
3.85 EUR +1.58% Intraday chart for DISCOUNT OPTIONSSCHEIN - FRESENIUS
Current month-5.01%
1 month-8.89%
Date Price Change
24-05-29 3.85 +1.58%
24-05-28 3.79 +1.07%
24-05-27 3.75 -2.09%
24-05-24 3.83 -5.67%
24-05-23 4.06 -5.14%

Delayed Quote Deutsche Boerse AG

Last update May 29, 2024 at 04:34 am

More quotes

Static data

Product typeExotische Produkte
Buy / SellPUT
Underlying FRESENIUS SE & CO. KGAA
IssuerLogo Issuer Vontobel Vontobel
WKN VM3AUL
ISINDE000VM3AUL7
Date issued 2023-10-03
Strike 35
Maturity 2024-09-20 (115 Days)
Parity 1 : 1
Emission price 3.31
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 4.67
Lowest since issue 3.12
Spread 0.03
Spread %0.76%

Company Profile

Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - hospital administration and engineering (64.3%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (35.7%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (72.4%), North America (12.3%), Asia/Pacific (7.3%), Latin America (6.4%) and Africa (1.6%).
Sector
-
More about the company

Ratings for Fresenius SE & Co. KGaA

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Fresenius SE & Co. KGaA

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
29.23 EUR
Average target price
36.72 EUR
Spread / Average Target
+25.64%
Consensus